CRISPR THERAPEUTICS AG (CRSP) Stock News
NASDAQ:CRSP - Nasdaq - CH0334081137 - Common Stock - Currency: USD
CRSP Latest News, Press Relases and Analysis
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
If you're looking to add growth to your portfolio, biotech stocks can be a great choice. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months.
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pooled research found that sweat chloride (SwCl) levels […]
Biotech Stock for Options Bears to Target Right Now
CRSP is flashing a historically bearish signal
Prediction: This Monster Artificial Intelligence (AI) Software Stock Could Be Wall Street's Next Stock-Split Candidate (Hint: It's Not Palantir)
Artificial intelligence (AI) software stocks have been a favorite among growth investors over the last couple of years.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: EXAS
Red Canary Acquisition, AI Innovations Propel Zscaler's Growth Story: Analyst
Needham analyst Mike Cikos maintained a Buy rating on Zscaler (NASDAQ:ZS) and raised the price forecast from $310 to $350. On June 3, Cikos attended Zscaler’s annual Zenith event, the company’s flagship gathering for customers and partners. In an analyst note, he said that the company unveiled several new capabilities, primarily focused on AI and the expansion of its Zero Trust Everywhere initiative. These enhancements aim to bolster data security and thwart cyberattacks, directly addressing cri
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
CRISPR Therapeutics has the potential to generate significant breakthroughs in gene editing. Regeneron's biggest growth driver is still performing well, and it is developing newer medicines. For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: CRISPR Therapeutics (NASDAQ: CRSP) and Regeneron Pharmaceuticals (NASDAQ: REGN).
3 Best Growth Stocks to Buy in June
Growth investors have had to work harder than usual to find winners in 2025. With the S&P 500 essentially flat year to date amid President Trump's global trade reset and persistent inflation concerns, the easy gains of prior years have evaporated. While the average stock treads water, companies with genuine competitive advantages and exposure to secular growth themes are posting triple-digit gains.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Big Money Keeps Buying Palantir
Big Money inflows push shares of data mining company Palantir Technologies, Inc. (PLTR) higher.
F5 and Red Hat Expand AI Collaboration for Secure, Scalable Applications
On May 19, F5, Inc. (NASDAQ:FFIV) announced an enhanced partnership with Red Hat, the leading provider of open-source solutions, aimed at helping enterprises securely deploy and scale high-performance AI applications. The collaboration enables businesses to accelerate retrieval-augmented generation (RAG), model serving, and scalable data ingestion, fostering AI adoption without compromising security. AI deployment is surging, […]
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
YouTube-Like Platform Bilibili Keeps China's Average 26-Year-Old More Engaged Than Ever, Stock Soars
Bilibili Inc. (NASDAQ:BILI) on Tuesday announced its fiscal first-quarter results, revealing a 24% year-over-year increase in quarterly revenue to $965.1 million (7 billion Chinese yuan), surpassing the analyst consensus estimate of $947.72 million. The Chinese video-sharing platform’s adjusted EPADS of 12 cents beat the analyst consensus estimate of 6 cents. Bilibili is often compared to YouTube due to its focus on long-form video content, user-generated content, and interactive features like l
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small...
2 Stocks Down 63% and 36% to Buy Right Now
Target is a Dividend King with a high yield, and the company should eventually get back to higher growth. Airbnb has been serving up impressive margins, and new expansion bets could help supercharge the stock. Pivots on tariff and trade policy, shifting outlooks on interest rate policies, corporate earnings of varying quality, and other factors have all combined to create a stretch of nearly unprecedented volatility for stocks.
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
Shares of CRISPR Therapeutics have lost momentum in recent years. Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while the S&P 500 has gained 41%.
3 Stocks That Cut You a Check Each Month
Yes, it's possible to collect investment income at the same pace that you spend money.
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders
Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?
CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages. One of them is CRISPR Therapeutics (NASDAQ: CRSP). Its financials haven't been looking all that impressive and as a result, growth investors have been dumping the stock.
Is Amgen Inc. (AMGN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?
We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Trump Incentivizes Pharmaceuticals to Build Domestic Manufacturing Capacity […]
Is Vertiv Holdings Co (VRT) The Most Crowded Hedge Fund Stock That is Targeted by Short Sellers?
We recently published a list of 15 Most Crowded Hedge Fund Stocks That Are Targeted by Short Sellers. In this article, we are going to take a look at where Vertiv Holdings Co (NYSE:VRT) stands against other most crowded hedge fund stocks that are targeted by short sellers. Hedge funds piling into a stock is […]
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.